14. The composition of claims 1-13, comprising the components in the proportions listed in Table 17.

15. The composition of claims 1-14, wherein said composition, upon contact with a cell expressing Eg5, inhibits expression of Eg5 by at least 40, 50, 60, 70, 80, or by at least 90%.

16. The composition of claims 1-15, wherein said composition, upon contact with a cell expressing VEGF, inhibits expression of VEGF by at least 40, 50, 60, 70, 80, or by at least 90%.

17. The composition of claims 1-16, wherein administration of said composition to a cell decreases expression of both Eg5 and VEGF in said cell.

18. The composition of claims 1-17, wherein the composition is administered in a nM concentration.

19. The composition of claims 1-18, wherein administration of said composition to a cell increases mono-aster formation in the cell.

20. The composition of claims 1-19, wherein administration of said composition to a mammal results in at least one effect selected from the group consisting of prevention of tumor growth, reduction in tumor growth, or prolonged survival in said mammal.

21. The composition of claims 1-20, wherein said effect is measured using at least one assay selected from the group consisting of determination of body weight, determination of organ weight, visual inspection, mRNA analysis, serum AFP analysis and survival monitoring.

22. The composition of claims 1-21, further comprising Sorafenib.

23. The composition of any of the above claims, wherein the first dsRNA contains two overhangs and the second dsRNA contains an overhang at the 3' of the antisense and a blunt end at the 5' end of the antisense strand.

~~24. A method for inhibiting the expression of Eg5/KSP and VEGF in a cell comprising administering any of the compositions of claims 1-22 to the cell.~~

~~25.~~24. ~~A method for preventing tumor growth, reducing tumor growth, or prolonging survival in a mammal in need of treatment for cancer comprising administering the~~ The composition of claims 1-22 ~~to said mammal~~for use in preventing tumor growth, reducing tumor growth, or prolonging survival in a mammal.

~~26.~~25. The ~~method~~ composition of claim ~~25~~24, wherein said mammal has liver cancer.

~~27.~~26. The ~~method~~ composition of claim ~~25~~24, wherein said mammal is a human with liver cancer.

~~28.~~27. The ~~method~~ composition of claim 24 ~~or 25~~, further comprising ~~administering~~ Sorafenib.

28. Use of a composition of claims 1-22 in the manufacture of a medicament for preventing tumor growth, reducing tumor growth, or prolonging survival in a mammal.

29. The use of claim 28, wherein said mammal has liver cancer.

30. The use of claim 28, wherein said mammal is a human with liver cancer.

31. The use of claim 28, further comprising Sorafenib.